The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.
The US Senate has passed a bill that would require the FDA to beef up education on biosimilars in order to improve uptake of these lower-cost agents, which are considered as safe and efficacious as the originator biologics they are patterned after.
The Advancing Education on Biosimilars Act was approved unanimously. The bill (S 1681) was co-sponsored by Senator Maggie Hassan, D-New Hampshire. “Our bipartisan legislation will help lower the cost of health care by educating more Granite Staters and Americans about biosimilars—an under-the-radar alternative to expensive brand-name drugs,” Hassan said in a statement.
The Senate version of the bill was introduced in May 2019 and was voted on successfully in December 2020 but required a fresh vote this year.
Under the bill, the FDA would be required to create a biosimilars education website with information on biosimilars and other biologics covering key statutory and regulatory terms used to describe and classify biosimilars, such as interchangeability. It would have to be tailored to the unique needs of health care providers, meaning the material should be appropriately presented and explained.
The bill would also require that comparative data for originator biologics and biosimilars is made available; and, on an ongoing basis, continuing education programs would have to be maintained to inform health care providers, including nurses, about biosimilars.
A House version of the bill (HR 4400) was introduced in September 2019 and referred to the Subcommittee on Health.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.